Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016–2023 - Top-Institutions - MDSpire

Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016–2023

  • By

  • Eric A F Simões

  • Robert J Suss

  • Dhananjay Raje

  • July 16, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Public Health

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Pulmonology
    • Geriatrics

  • #3

    University of Colorado Anschutz Medical Campus
    University of Colorado Anschutz Medical Campus

    Aurora, CO

    Key Differentiators

    • Infectious Diseases
    • Pulmonology
    • Epidemiology

  • #4

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Infectious Diseases
    • Pulmonology
    • Geriatrics

  • #5

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, TN

    Key Differentiators

    • Infectious Diseases
    • Pulmonology
    • Epidemiology

Original Source(s)

Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016–2023

  • by Eric A F Simões, Robert J Suss, Dhananjay Raje

  • July 16, 2025

Related Content

N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR)

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study

Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

Interim CDC estimates found the 2025–2026 vaccine reduced outpatient influenza visits by up to 41% and hospitalizations by up to 41%.